Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Orchestra BioMed Holdings (OBIO) Change in Accured Expenses (2022 - 2025)

Orchestra BioMed Holdings (OBIO) has disclosed Change in Accured Expenses for 4 consecutive years, with $3.4 million as the latest value for Q3 2025.

  • On a quarterly basis, Change in Accured Expenses rose 176.95% to $3.4 million in Q3 2025 year-over-year; TTM through Sep 2025 was $3.6 million, a 14.04% decrease, with the full-year FY2024 number at $3.0 million, up 1947.59% from a year prior.
  • Change in Accured Expenses was $3.4 million for Q3 2025 at Orchestra BioMed Holdings, up from $1.1 million in the prior quarter.
  • In the past five years, Change in Accured Expenses ranged from a high of $3.7 million in Q2 2024 to a low of -$1.8 million in Q1 2023.
  • A 4-year average of $717733.3 and a median of $668000.0 in 2023 define the central range for Change in Accured Expenses.
  • Peak YoY movement for Change in Accured Expenses: plummeted 988.61% in 2023, then skyrocketed 378.31% in 2024.
  • Orchestra BioMed Holdings' Change in Accured Expenses stood at $1.1 million in 2022, then crashed by 53.4% to $493000.0 in 2023, then crashed by 244.42% to -$712000.0 in 2024, then surged by 579.21% to $3.4 million in 2025.
  • Per Business Quant, the three most recent readings for OBIO's Change in Accured Expenses are $3.4 million (Q3 2025), $1.1 million (Q2 2025), and -$202000.0 (Q1 2025).